Nasdaq · CIK 0001728117
GOSS Gossamer Bio, Inc.
Insider trading from SEC Form 4. Last filing 17 d ago.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company
Signals
Open-market buys and sells at Gossamer Bio, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 32Weak | Sandra Milligan director buy | $50k 26,050 shares | +81% | - |
Transactions
The last 20 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | Russell J. Cox director | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | 17 d ago |
| Sep 23, 2026 | Thomas O Daniel director | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | 17 d ago |
| Sep 23, 2026 | Skye Drynan director | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | 17 d ago |
| Sep 23, 2026 | Steven D Nathan director | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | 17 d ago |
| Sep 23, 2026 | John D Quisel director | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | 17 d ago |
| Sep 23, 2026 | Sandra Milligan director | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | 17 d ago |
| Sep 23, 2026 | Gregory Austin Ciongoli director | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | 17 d ago |
| Aug 19, 2025 | Sandra Milligan director | POpen-market purchase Common Stock | +26,050 | $1.92 | $50k | 58,050 | Aug 20, 2025 |
| Jun 25, 2025 | Skye Drynan director | AGrant or award Stock Option (Right to Buy)derivative | +115,000 | $0.00 | $0 | 115,000 | Jun 26, 2025 |
| Jun 25, 2025 | Steven D Nathan director | AGrant or award Stock Option (Right to Buy)derivative | +115,000 | $0.00 | $0 | 115,000 | Jun 26, 2025 |
| Jun 25, 2025 | John D Quisel director | AGrant or award Stock Option (Right to Buy)derivative | +115,000 | $0.00 | $0 | 115,000 | Jun 26, 2025 |
| Jun 25, 2025 | Sandra Milligan director | AGrant or award Stock Option (Right to Buy)derivative | +115,000 | $0.00 | $0 | 115,000 | Jun 26, 2025 |
| Jun 25, 2025 | Thomas O Daniel director | AGrant or award Stock Option (Right to Buy)derivative | +115,000 | $0.00 | $0 | 115,000 | Jun 26, 2025 |
| Jun 25, 2025 | Russell J. Cox director | AGrant or award Stock Option (Right to Buy)derivative | +115,000 | $0.00 | $0 | 115,000 | Jun 26, 2025 |
| Mar 4, 2025 | Richard Aranda Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +572,000 | $0.00 | $0 | 572,000 | Mar 6, 2025 |
| Mar 4, 2025 | Waage Christian EVP, Tech Ops and Admin | AGrant or award Stock Option (Right to Buy)derivative | +440,000 | $0.00 | $0 | 440,000 | Mar 6, 2025 |
| Mar 4, 2025 | Bryan Giraudo COO/CFO | AGrant or award Stock Option (Right to Buy)derivative | +638,000 | $0.00 | $0 | 638,000 | Mar 6, 2025 |
| Mar 4, 2025 | Faheem Hasnain President & CEO | AGrant or award Stock Option (Right to Buy)derivative | +1,540,000 | $0.00 | $0 | 1,540,000 | Mar 6, 2025 |
| Mar 4, 2025 | Robert Paul Smith JR Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +572,000 | $0.00 | $0 | 572,000 | Mar 6, 2025 |
| Mar 4, 2025 | Caryn Peterson EVP, Regulatory Affairs | AGrant or award Stock Option (Right to Buy)derivative | +440,000 | $0.00 | $0 | 440,000 | Mar 6, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Richard ArandaChief Medical Officer
- Waage ChristianEVP, Tech Ops and Admin
- Gregory Austin Ciongolidirector, owner, other
- Russell J. Coxdirector
- Thomas O Danieldirector
- Skye Drynandirector
- Bryan GiraudoCOO/CFO
- Faheem HasnainPresident & CEO
- Sandra Milliganpresident, officer, ceo, director
- Steven D Nathandirector
- Caryn PetersonEVP, Regulatory Affairs
- John D Quiselceo, officer, director
- Robert Paul Smith JRChief Commercial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.